Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas

Preoperative Platelet Count and Survival Prognosis in Resected Pancreatic Ductal Adenocarcinoma

“…Brown, et al [24] reported the same relation, and so have other reports on gastric, endometrial, cervical, and metastatic renal cell carcinoma [11,14,19,30]. However, in our cohort, neither high WBC nor low hemoglobin counts were associated with poor survival.…”

“…Brown, et al evaluated 109 patients who underwent pancreatic resection for ductal adenocarcinoma. They found that the median survival of patients with a high preoperative platelet count was significantly worse than that of patients with a platelet count of<300 × 10 3 / l (11.2 and 18.6 months, respectively) [24]. In another study, Suzuki, et al found a mean disease-free interval of only 4.9 months in patients with high platelet count, compared to 46.5 months in patients with a platelet count of<400 × 10 3 / l. This striking difference, however, is questionable, because many patients were censored in the disease-free interval curve before the median was reached, and their cause and number are not stated [25].…”

Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer

“…The present study investigated this role of BRAF mutation in a Chinese cohort by examining its relationship with clinicopathological characteristics of PTC. To this end, we also investigated the relationship of BRAF mutation with peripheral blood platelet counts as thrombocytosis is associated with various human cancers and their poor prognosis (Hernandez et al 2000, Ikeda et al 2002, Verheul & Pinedo 2003, Shimada et al 2004, Brown et al 2005, Bensalah et al 2006. We found a close association of the T1799A BRAF mutation with extrathyroidal invasion and advanced tumor stages (III and IV) in this Chinese cohort of PTC.…”

“…Association of BRAF mutation in PTC with higher peripheral blood platelet counts Prompted by previous findings that elevated peripheral blood platelet count was associated with some human cancers and their aggressiveness (Hernandez et al 2000, Ikeda et al 2002, Verheul & Pinedo 2003, Shimada et al 2004, Brown et al 2005, Bensalah et al 2006, we analyzed the relationship of the BRAF mutation with platelet count and several other hematological and biochemical parameters. This represented an attempt to see if a higher platelet count played any role in BRAF mutation-associated tumor aggressiveness of PTC.…”

“…In the present report, we investigated the relationship of the T1799A BRAF mutation with clinicopathological characteristics of PTC and peripheral platelet counts which are often associated with aggressiveness of other human cancers (Hernandez et al 2000, Ikeda et al 2002, Verheul & Pinedo 2003, Shimada et al 2004, Brown et al 2005, Bensalah et al 2006 to examine the role of this mutation in PTC in Chinese where this mutation has not been well studied.…”